244192-94-7
244192-94-7 structure
- Name: L-748,337
- Chemical Name: L-748,337,N-[[3-[(2S)-2-Hydroxy-3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl]methyl]-acetamide
- CAS Number: 244192-94-7
- Molecular Formula: C26H31N3O5S
- Molecular Weight: 497.60600
- Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
- Create Date: 2016-10-14 03:33:18
- Modify Date: 2025-08-27 13:37:51
-
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The Ki values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively[1]. L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6[2]. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases[1][2][3].
| Name | L-748,337,N-[[3-[(2S)-2-Hydroxy-3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl]methyl]-acetamide |
|---|---|
| Synonyms |
L 748,337
6-Chloromelatonin |
| Description | L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The Ki values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively[1]. L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6[2]. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Beta-3 adrenergic receptor:4 nM (Ki) Beta-2 adrenergic receptor:204 nM (Ki) Beta-1 adrenergic receptor:390 nM (Ki) |
| In Vitro | L748337 (1 μM) inhibits iNOS expression in B16F10 cells[1]. |
| In Vivo | L-748337 (intraperitoneal injection; 5 mg/kg; beginning 10 days until D18) decreases the growth of melanoma induced by B16F10 cell inoculation and decreases tumor vasculature in mice[1]. Animal Model: Fifty male C57BL/6 J mice (8 weeks of age) bearing syngeneic B16F10 cell[1] Dosage: 5 mg/kg Administration: Beginning 10 days until D18 Result: Exhibited anti-cancer effects. |
| References |
| Molecular Formula | C26H31N3O5S |
|---|---|
| Molecular Weight | 497.60600 |
| Exact Mass | 497.19800 |
| PSA | 125.14000 |
| LogP | 4.63110 |